Franklin-based Lynch Regenerative Medicine LLC raises Series A financing round
The funding will allow the company to develop and commercialize innovative skin rejuvenation and regeneration solutions based on pure platelet-derived growth factor.
Lynch Regenerative Medicine LLC (LRM) of Franklin, TN has completed its Series A financing to develop and commercialize innovative skin rejuvenation and regeneration solutions based on pure platelet-derived growth factor (PDGF). It is the only tissue growth factor that has been approved by the U.S. Food and Drug Administration and other international regulatory bodies to be safe and effective in human tissue regeneration and wound healing. pure platelet-derived growth factor (PDGF).
LRM’s Series A financing round was led by Champion VC, a family office investor managing the assets of members of the Frist family, and Dr. Samuel Lynch, Founder and Chief Executive Officer of LRM. It is at least the third start-up in the regenerative medicine space that Lynch, a former Chair of the Board of Life Science Tennessee and , has founded.
Prior to launching LRM in November 2022, according to his LinkedIn profile, Lynch founded two other companies that he successfully exited – Lynch Biologics that was acquired by Geistlich Pharma North America, a division of Geistlich Pharma AG, the world’s leading dental regenerative biomaterials company, in October 2022, and BioMimetic Therapeutics USA Inc. that was acquired by Wright Medical Technology in 2013 and is now a large portion of Stryker’s biologic products portfolio.
Lynch has two doctorates, including one from Harvard Medical School, extensive achievements in healthcare, and is a successful entrepreneur and businessperson. After 10 years of training, teaching, patient care and clinical and scientific research at Harvard, he joined Sankyo (now Daiichi Sankyo) where he turned around a struggling wholly owned subsidiary over his five year tenure. Lynch then founded BioMimetic, leading it from inception to multiple financings to an initial public offering to a trade sale valued at $400 million. He has more than 200 patents and publications at last count.
According to a news release from the company, the patented pure PDGF-based technology is currently the main active component in four FDA-approved products, including two products for improving healing and regeneration of orthopedic tissues, and one product each for improving the healing and regeneration of periodontal tissues and skin. These products have helped millions of patients around the world over the past 15 years. Now LRM is applying this proven technology to skin aesthetics.
“I’ve spent my career studying regenerative medicine and developing and commercializing PDGF products to regenerate tissues lost due to trauma or disease,” said Lynch, who is recognized worldwide as one of the leading experts on tissue growth factors. “I’m most excited to bring pure PDGF-based solutions to the skincare market, where we see the largest unmet need for proven solutions for skin rejuvenation and regeneration.”
LRM’s first product to improve skin aesthetics, AriessenceÔ Pure PDGF+, is available today and can be found in leading innovative med/spa clinics and other aesthetic-focused offices, including dermatology and plastic surgery practices. Ariessence Pure PDGF+ is used topically to improve aesthetic outcomes associated with procedures such as micro-needling, dermabrasion, lasers, plastic surgery and other procedures where the appearance of healthier-looking skin can be accelerated and enhanced using growth factors such as PDGF.
“Growth factors are playing an important role in skincare today, but there are no other solutions backed by the level of scientific and clinical evidence that supports the safety and effectiveness of pure PDGF,” said Lynch. “Arriessence Pure PDGF+ builds on this truly unique foundation of success in regenerative medicine.”
LRM will use the capital from the Series A financing to fuel its commercialization strategy. With the successful closing of this Series A round, LRM plans to expand its team, bringing in additional top-tier talent across various disciplines, including commercialization, business development, clinical development, and regulatory affairs.
Like what you've read?
Forward to a friend!